A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+HER2L primary breast cancer (BC)

被引：55

作者：

Loi, S. ^{[1
]}

Curigliano, G. ^{[2
,3
]}

Salgado, R. F. ^{[4
]}

Diaz, R. I. Romero ^{[5
]}

Delaloge, S. ^{[6
]}

Rojas, C. ^{[7
]}

Kok, M. ^{[8
]}

Manich, C. Saura ^{[9
]}

Harbeck, N. ^{[10
]}

Mittendorf, E. A. ^{[11
]}

Yardley, D. ^{[12
]}

Pusztai, L. ^{[13
]}

Zaizar, A. Suarez ^{[14
]}

Ungureanu, A. ^{[15
]}

Ades, F. ^{[16
]}

Chandra, R. ^{[17
]}

Nathani, R. ^{[18
]}

Pacius, M. ^{[19
]}

Wu, J. Q. ^{[20
]}

McArthur, H. L. ^{[21
]}

机构：

[1] Peter MacCallum Canc Ctr, Div Res & Clin Med, Melbourne, Vic, Australia

[2] IRCCS, European Inst Oncol, Oncol & Hemato Oncol, Milan, Italy

[3] Univ Milan, Milan, Italy

[4] GZA Ziekenhuizen, Dept Pathol, Campus St Augustinus, Antwerp, Belgium

[5] Consulta Externa, Consultorio Oncol Med, Tlalnepantla Baz, Mexico

[6] Inst Gustave Roussy, Breast Oncol Dept, Villejuif, France

[7] Med Oncol, Bradford Hill, Santiago, Chile

[8] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[9] Vall Hebron Univ Hosp, Breast Canc Program, Barcelona, Spain

[10] Ludwig Maximilians Univ Hosp, Comprehens Canc Ctr Munich, Dept Gynecol & Obstet, Breast Ctr, Munich, Germany

[11] Brigham & Womens Canc Ctr, Dana Farber, Surg, Boston, MA USA

[12] Sarah Cannon Res Ctr & Tennessee Oncol, Res Inst, Chattanooga, TN USA

[13] Yale Univ, Yale Canc Ctr, Smilow Canc Hosp, Sch Med, New Heaven, TX USA

[14] CENEIT Oncol, Oncol, Mexico City, Mexico

[15] Amethyst Radiotherapy Ctr Cluj, Oncol Dept, Floresti, Romania

[16] Bristol Myers Squibb, Global Drug Dev, Lawrenceville, GA USA

[17] BMS Bristol Myers Squibb, Heme Oncol Cell & Gene Therapy, Cambridge, MA USA

[18] Bristol Myers Squibb, Global Oncol Clin Dev, Bristol, MA USA

[19] BMS Bristol Myers Squibb, Global Biometr & Data Sci GBDS, Cambridge, MA USA

[20] BMS Bristol Myers Squibb, Translat Med Clin Biomarker, Cambridge, MA USA

[21] Univ Texas SouthWestern Med Ctr Dallas, Med, Dallas, TX USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA20

引用

页码：S1259 / S1260

页数：2